Literature DB >> 32368053

Transferrin Conjugated pH- and Redox-Responsive Poly(Amidoamine) Dendrimer Conjugate as an Efficient Drug Delivery Carrier for Cancer Therapy.

Qing Hu1,2, Yifei Wang1, Lu Xu1, Dawei Chen1,3, Lifang Cheng1.   

Abstract

INTRODUCTION: A multifunctional redox- and pH-responsive polymeric drug delivery system is designed and investigated for targeted anticancer drug delivery to liver cancer.
METHODS: The nanocarrier (His-PAMAM-ss-PEG-Tf, HP-ss-PEG-Tf) is constructed based on generation 4 polyamidoamine dendrimer (G4 PAMAM). Optimized amount of histidine (His) residues is grafted on the surface of PAMAM to obtain enhanced pH-sensitivity and proton-buffering capacity. Disulfide bonds (ss) are introduced between PAMAM and PEG to reach accelerated intracellular drug release. Transferrin (Tf) was applied to achieve active tumor targeting. Doxorubicin (DOX) is loaded in the hydrophobic cavity of the nanocarrier to exert its anti-tumor effect.
RESULTS: The results obtained from in vitro and in vivo evaluation indicate that HP-ss-PEG-Tf/DOX complex has pH and redox dual-sensitive properties, and exhibit higher cellular uptake and cytotoxicity than the other control groups. Flow cytometry and confocal microscopy display internalization of HP-ss-PEG-Tf/DOX via clathrin mediated endocytosis and effective endosomal escape in HepG2 cancer cells. Additionally, cyanine 7 labeled HP-ss-PEG-Tf conjugate could quickly accumulate in the HepG2 tumor. Remarkably, HP-ss-PEG-Tf/DOX present superior anticancer activity, enhanced apoptotic activity and lower heart and kidney toxicity in vivo. DISCUSSION: Thus, HP-ss-PEG-Tf is proved to be a promising candidate for effective targeting delivery of DOX into the tumor.
© 2020 Hu et al.

Entities:  

Keywords:  histidine; pH and redox sensitivity; poly(amidoamine) dendrimers; doxorubicin; transferrin

Mesh:

Substances:

Year:  2020        PMID: 32368053      PMCID: PMC7184127          DOI: 10.2147/IJN.S238536

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  38 in total

1.  Erratum to: PEGylated PAMAM Dendrimer-Doxorubicin Conjugates: In Vitro Evaluation and In Vivo Tumor Accumulation.

Authors:  Saijie Zhu; Minghuang Hong; Lihong Zhang; Guotao Tang; Yanyan Jiang; Yuanying Pei
Journal:  Pharm Res       Date:  2010-09       Impact factor: 4.200

Review 2.  Dendrimers in biomedical applications--reflections on the field.

Authors:  Sönke Svenson; Donald A Tomalia
Journal:  Adv Drug Deliv Rev       Date:  2005-11-21       Impact factor: 15.470

3.  Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles.

Authors:  Qing Xu; Yuexian Liu; Shishuai Su; Wei Li; Chunying Chen; Yan Wu
Journal:  Biomaterials       Date:  2011-11-25       Impact factor: 12.479

4.  Biodegradable micelles with sheddable poly(ethylene glycol) shells for triggered intracellular release of doxorubicin.

Authors:  Huanli Sun; Bingnan Guo; Ru Cheng; Fenghua Meng; Haiyan Liu; Zhiyuan Zhong
Journal:  Biomaterials       Date:  2009-08-08       Impact factor: 12.479

5.  Specifically Increased Paclitaxel Release in Tumor and Synergetic Therapy by a Hyaluronic Acid-Tocopherol Nanomicelle.

Authors:  Hanbo Zhang; Wei Li; Xiaomeng Guo; Fenfen Kong; Zuhua Wang; Chunqi Zhu; Lihua Luo; Qingpo Li; Jie Yang; Yongzhong Du; Jian You
Journal:  ACS Appl Mater Interfaces       Date:  2017-06-06       Impact factor: 9.229

6.  Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin.

Authors:  Wen Hu; Lipeng Qiu; Liang Cheng; Qing Hu; Yang Liu; Ziyang Hu; Dawei Chen; Lifang Cheng
Journal:  Acta Biomater       Date:  2016-03-16       Impact factor: 8.947

7.  Construction and evaluation of PAMAM-DOX conjugates with superior tumor recognition and intracellular acid-triggered drug release properties.

Authors:  Lifang Cheng; Qing Hu; Liang Cheng; Wen Hu; Ming Xu; Yaqin Zhu; Lu Zhang; Dawei Chen
Journal:  Colloids Surf B Biointerfaces       Date:  2015-05-01       Impact factor: 5.268

8.  Preparation and characterization of nanoparticles based on histidine-hyaluronic acid conjugates as doxorubicin carriers.

Authors:  Jing-liang Wu; Chen-guang Liu; Xiao-lei Wang; Zhen-hua Huang
Journal:  J Mater Sci Mater Med       Date:  2012-05-12       Impact factor: 3.896

9.  Physicochemical characteristics of pH-sensitive poly(L-histidine)-b-poly(ethylene glycol)/poly(L-lactide)-b-poly(ethylene glycol) mixed micelles.

Authors:  Haiqing Yin; Eun Seong Lee; Dongin Kim; Kwang Hee Lee; Kyung T Oh; You Han Bae
Journal:  J Control Release       Date:  2007-12-04       Impact factor: 9.776

10.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Authors:  Gail D Lewis Phillips; Guangmin Li; Debra L Dugger; Lisa M Crocker; Kathryn L Parsons; Elaine Mai; Walter A Blättler; John M Lambert; Ravi V J Chari; Robert J Lutz; Wai Lee T Wong; Frederic S Jacobson; Hartmut Koeppen; Ralph H Schwall; Sara R Kenkare-Mitra; Susan D Spencer; Mark X Sliwkowski
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 13.312

View more
  3 in total

Review 1.  Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.

Authors:  Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-12

Review 2.  Smart Nanomaterials for Biomedical Applications-A Review.

Authors:  Magdalena Aflori
Journal:  Nanomaterials (Basel)       Date:  2021-02-04       Impact factor: 5.076

3.  A dual-functional nanovehicle with fluorescent tracking and its targeted killing effects on hepatocellular carcinoma cells.

Authors:  Xiaojie Zhang; Qiming Gao; Qianfen Zhuang; Lu Zhang; Sihan Wang; Libo Du; Wenxi Yuan; Caifang Wang; Qiu Tian; Hua Yu; Yuming Zhao; Yang Liu
Journal:  RSC Adv       Date:  2021-03-16       Impact factor: 3.361

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.